Matinas Biopharma Holdings Stock Performance
| MTNB Stock | USD 0.59 0.01 1.67% |
The company secures a Beta (Market Risk) of 0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Matinas BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Matinas BioPharma is expected to be smaller as well. At this point, Matinas BioPharma has a negative expected return of -1.67%. Please make sure to verify Matinas BioPharma's kurtosis, as well as the relationship between the day median price and relative strength index , to decide if Matinas BioPharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Matinas BioPharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:50 | Last Split Date 2024-09-03 |
1 | Published on 2025-10-10 085638 - newser.com | 10/10/2025 |
2 | Will Matinas Biopharma Holdings Inc. stock test record highs in 2025 - Market Trend Report Weekly Top Gainers Trade List - newser.com | 10/27/2025 |
3 | What technical charts say about Matinas BioPharma Holdings Inc. stock - July 2025 Fed Impact AI Optimized Trading Strategy Guides - newser.com | 10/30/2025 |
4 | Is Matinas Biopharma Holdings Inc. stock supported by free cash flow - July 2025 Decliners Fast Exit Strategy with Risk Control - newser.com | 11/05/2025 |
5 | Why Matinas Biopharma Holdings Inc. stock benefits from AI revolution - 2025 Buyback Activity Entry Point Confirmation Alerts - newser.com | 11/12/2025 |
6 | How Matinas Biopharma Holdings Inc. stock moves on employment data - July 2025 Reactions AI Powered Market Entry Ideas - newser.com | 11/18/2025 |
7 | Breakout Watch Can Matinas BioPharma Holdings Inc. stock beat market expectations this quarter - Portfolio Performance Report Capital Efficiency Focused Ideas - | 12/19/2025 |
| Begin Period Cash Flow | 5 M | |
| Total Cashflows From Investing Activities | 9.2 M |
Matinas BioPharma Relative Risk vs. Return Landscape
If you would invest 193.00 in Matinas BioPharma Holdings on October 2, 2025 and sell it today you would lose (134.00) from holding Matinas BioPharma Holdings or give up 69.43% of portfolio value over 90 days. Matinas BioPharma Holdings is currently does not generate positive expected returns and assumes 6.4667% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Matinas, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Matinas BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Matinas BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Matinas BioPharma Holdings, and traders can use it to determine the average amount a Matinas BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2577
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MTNB |
Based on monthly moving average Matinas BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Matinas BioPharma by adding Matinas BioPharma to a well-diversified portfolio.
Matinas BioPharma Fundamentals Growth
Matinas Stock prices reflect investors' perceptions of the future prospects and financial health of Matinas BioPharma, and Matinas BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Matinas Stock performance.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 867.63 K | ||||
| Shares Outstanding | 6.41 M | ||||
| Price To Earning | (2.43) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 46.50 X | ||||
| Gross Profit | (2.46 M) | ||||
| EBITDA | (19.19 M) | ||||
| Net Income | (24.25 M) | ||||
| Cash And Equivalents | 38.5 M | ||||
| Cash Per Share | 0.18 X | ||||
| Total Debt | 2.89 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 7.79 X | ||||
| Book Value Per Share | 1.09 X | ||||
| Cash Flow From Operations | (15.88 M) | ||||
| Earnings Per Share | (3.42) X | ||||
| Market Capitalization | 3.84 M | ||||
| Total Asset | 12.64 M | ||||
| Retained Earnings | (199.82 M) | ||||
| Working Capital | 5.36 M | ||||
| Current Asset | 6.53 M | ||||
| Current Liabilities | 1.36 M | ||||
About Matinas BioPharma Performance
By analyzing Matinas BioPharma's fundamental ratios, stakeholders can gain valuable insights into Matinas BioPharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Matinas BioPharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Matinas BioPharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.34) | (2.22) | |
| Return On Capital Employed | (2.02) | (1.92) | |
| Return On Assets | (1.92) | (1.82) | |
| Return On Equity | (3.20) | (3.04) |
Things to note about Matinas BioPharma performance evaluation
Checking the ongoing alerts about Matinas BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Matinas BioPharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Matinas BioPharma generated a negative expected return over the last 90 days | |
| Matinas BioPharma has high historical volatility and very poor performance | |
| Matinas BioPharma has some characteristics of a very speculative penny stock | |
| Matinas BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (24.25 M) with loss before overhead, payroll, taxes, and interest of (2.46 M). | |
| Matinas BioPharma Holdings currently holds about 38.5 M in cash with (15.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.18. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Breakout Watch Can Matinas BioPharma Holdings Inc. stock beat market expectations this quarter - Portfolio Performance Report Capital Efficiency Focused Ideas - |
- Analyzing Matinas BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Matinas BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Matinas BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Matinas BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Matinas BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Matinas BioPharma's stock. These opinions can provide insight into Matinas BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Matinas Stock analysis
When running Matinas BioPharma's price analysis, check to measure Matinas BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Matinas BioPharma is operating at the current time. Most of Matinas BioPharma's value examination focuses on studying past and present price action to predict the probability of Matinas BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Matinas BioPharma's price. Additionally, you may evaluate how the addition of Matinas BioPharma to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |